Information about http://www.villageventures.com/stuff/contentmgr/files/d765d70b30ba1f445c06d07719db9840/pdf/biolex_venturewire_050210.pdf

Biotech Company Biolex Names Dale Sander CFO By VentureWire Staff…

Tags: alfa interferon, biolex, biotech company, biotech firm, chief business officer, dow chemical, expression system, growth phase, hepatitis c, intersouth partners, kitty hawk, maxim pharmaceuticals inc, medical device company, mitsui co, protein recovery, quaker bioventures, staff reporters, street partners, therapeutic proteins, venture partners,
Pages: 1
Language: english
Created: Fri Feb 11 08:21:27 2005
Display cached document
Page 1
image
Biotech Company Biolex Names Dale Sander CFO
By VentureWire Staff Reporters                                       2/10/2005
Biopharmaceutical firm Biolex said Dale Sander had joined the company
as chief financial officer and senior vice president of finance as the
company begins an anticipated growth phase.

Sander, 45, came to Biolex from Maxim Pharmaceuticals Inc., where he
was chief financial officer where he directed financing transactions in the
U.S. and Europe and arranged partnerships for the company. He has also
held the top financial post at medical device company Tactyl Technologies
Inc. and public biotech firm Xytronyx Inc.

Sander "has obviously managed growth," according to Biolex's Chief
Business Officer John Irick.

Biolex uses its proprietary Lemna Expression system, or LEX, for
developing therapeutic proteins. The LEX system couples characteristics of
aquatic plant Lemna with genetic engineering and protein recovery
methods in order to create hard-to-make proteins such as peptides and
cytokines.

Biolex has raised $34 million to date from investors including Quaker
BioVentures, Intersouth Partners, Johnson & Johnson Development, Mitsui
& Co. Venture Partners, Dow Chemical, Dogwood Equity, Trelys Venture
Partners, Wakefield Group, Kitty Hawk Capital, Franklin Street Partners,
Tall Oaks Capital and Academy Centennial Fund.

The Pittsboro, N.C.-based company's lead product, Alfa Interferon, a
treatment for hepatitis c, is in Phase I clinical trials.

http://www.biolex.com